- Home
- ITGR vs KNSA Comparison
ITGR vs KNSA Comparison
Compare ITGR & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITGR | KNSA |
|---|---|---|
| Founded | 1970 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 2000 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ITGR | KNSA |
|---|---|---|
| Price | $82.74 | $38.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $95.00 | $51.33 |
| AVG Volume (30 Days) | ★ 625.0K | 510.1K |
| Earning Date | 02-19-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.42 | 0.47 |
| Revenue | ★ $1,831,074,000.00 | $597,973,000.00 |
| Revenue This Year | $9.58 | $61.60 |
| Revenue Next Year | N/A | $29.82 |
| P/E Ratio | ★ $34.46 | $88.08 |
| Revenue Growth | 9.54 | ★ 55.68 |
| 52 Week Low | $62.00 | $17.82 |
| 52 Week High | $146.36 | $44.42 |
Technical Indicators
Market Signals| Indicator | ITGR | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 65.03 | 36.23 |
| Support Level | $80.17 | $39.16 |
| Resistance Level | $85.23 | $43.00 |
| Average True Range (ATR) | 1.97 | 1.70 |
| MACD | 0.49 | -0.29 |
| Stochastic Oscillator | 70.90 | 6.41 |
Price Performance
Historical ComparisonAbout ITGR Integer Holdings Corporation
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.